Hussaarts, K.G.A.M.; van Doorn, L.; Bins, S.; Sprengers, D.; de Bruijn, P.; van Leeuwen, R.W.F.; Koolen, S.L.W.; van Gelder, T.; Mathijssen, R.H.J.
Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma. Pharmaceuticals 2021, 14, 46.
https://doi.org/10.3390/ph14010046
AMA Style
Hussaarts KGAM, van Doorn L, Bins S, Sprengers D, de Bruijn P, van Leeuwen RWF, Koolen SLW, van Gelder T, Mathijssen RHJ.
Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma. Pharmaceuticals. 2021; 14(1):46.
https://doi.org/10.3390/ph14010046
Chicago/Turabian Style
Hussaarts, Koen G. A. M., Leni van Doorn, Sander Bins, Dave Sprengers, Peter de Bruijn, Roelof W. F. van Leeuwen, Stijn L. W. Koolen, Teun van Gelder, and Ron H. J. Mathijssen.
2021. "Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma" Pharmaceuticals 14, no. 1: 46.
https://doi.org/10.3390/ph14010046
APA Style
Hussaarts, K. G. A. M., van Doorn, L., Bins, S., Sprengers, D., de Bruijn, P., van Leeuwen, R. W. F., Koolen, S. L. W., van Gelder, T., & Mathijssen, R. H. J.
(2021). Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma. Pharmaceuticals, 14(1), 46.
https://doi.org/10.3390/ph14010046
